NCT03451435 (NAC) is a EARLY_PHASE1 clinical trial of N acetyl cysteine in Endodontic Disease, sponsored by University of California, Los Angeles.

Who is sponsoring NCT03451435?

NCT03451435 is sponsored by University of California, Los Angeles.

What drugs are being tested in NCT03451435?

Interventions in NCT03451435: N acetyl cysteine.

What condition does NCT03451435 study?

NCT03451435 studies Endodontic Disease.

Is NCT03451435 still recruiting?

NCT03451435 is currently terminated. Last updated 21 January 2026.

Last reviewed 2026-01-21 · How we verify

NCT03451435: NAC

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

N-Acetyl Cysteine Protects Pulpal Stem Cells in Endodontic Revascularization

Terminated EARLY_PHASE1 Last updated 21 January 2026

What this trial tests

EARLY_PHASE1 trial testing N acetyl cysteine in Endodontic Disease in 7 participants. Terminated before completion.

Timeline

15 June 2018

Primary endpoint
1 April 2019

1 April 2019

Quick facts

Lead sponsor	University of California, Los Angeles
Phase	EARLY_PHASE1
Status	Terminated
Study type	INTERVENTIONAL
Allocation	randomized
Design	parallel
Masking	double
Primary purpose	treatment
Enrollment	7
Start date	15 June 2018
Primary completion	1 April 2019
Estimated completion	1 April 2019
Sites	1 location across United States

Drugs / interventions tested

N acetyl cysteine — full drug profile →

Conditions studied

Endodontic Disease — all drugs for Endodontic Disease →

Sponsor

University of California, Los Angeles

Who can join

Adults 6 to 18, any sex, with Endodontic Disease. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

Pulp re-vascularization/regeneration is a procedure performed to allow pulpal stem cells to survive and/or differentiate to allow immature tooth root structures to grow to full maturity. Currently, the procedure includes disinfection of the necrotic root canal space and induction of bleeding to potentiate pulpal stem cell differentiation to allow root growth on an immature root. A number of studies conducted previously demonstrate that N-acetyl cysteine (NAC) potentiates differentiation of pulpal stem/stromal cells and protects pulpal cells from apoptosis. 14-18 human subjects will be recruited forming two groups where pulp re-vascularization/regeneration procedures will be performed with or without the use of NAC treatment prior to induction of bleeding. Recall follow-up appointments will be done at 6 months and 1 year post treatment with subsequent yearly appointments until full root growth has been achieved.

Publications & conference data

1 peer-reviewed publication reference this trial (live from Europe PMC):

Research progress on optimization of <i>in vitro</i> isolation, cultivation and preservation methods of dental pulp stem cells for clinical application.
Wang X, Li F, Wu S, Xing W, et al · · 2024 · cited 6× · PMID 38633667 · DOI 10.3389/fbioe.2024.1305614

Verify or expand the search:

Other trials of N acetyl cysteine

Trials testing the same drug.

NCT06486805 — N-Acetyl Cysteine Effect on Liver Function After Mitral Valve Replacement · Phase 4 · completed
NCT06484530 — Gene-guided N-acetyl Cysteine for Prophylaxis of Anti-tuberculous Drug- Induced Hepatitis · Phase 4 · recruiting
NCT06297369 — Evaluation of the Effect of N-acetylcysteine in Preventing Cisplatin-Induced Toxicities in Cancer Patients · Phase 2 · unknown
NCT05944458 — Efficacy of Intravenous N-Acetylcysteine in Preventing Linezolid-Induced Thrombocytopenia in Critically Ill Patients · Phase 4 · completed
NCT05664789 — Targeting the Neurobiology of RRB in Autism Using N-acetylcysteine: Trial · Phase 2, PHASE3 · recruiting

Other recruiting trials for Endodontic Disease

Currently open trials in the same condition.

NCT07239505 — A Randomized Controlled Trial Evaluating Whether Pre-operative Trinase Reduces Post-operative Pain in Patients With Symp · NA · recruiting
NCT06948162 — Exploration of the Utility of Dental-dedicated MRI for Dentistry · recruiting
NCT06574152 — Effect of Photobiomodulation on Pain and Healing of the Vertical Releasing Incision After Endodontic Microsurgery · NA · recruiting
NCT05935306 — Effect of Photobiomodulation to Reduce Post-operative Pain After Endodontic Surgery · NA · recruiting
NCT06660797 — Irrigation Activating Techniques on Irrigant Penetration Depth and Microbial Reduction · NA · recruiting

Other University of California, Los Angeles trials

Trials by the same sponsor.

NCT04846517 — rTMS for Aneroxia Nervosa in Youth · NA · not yet recruiting
NCT06701760 — Sodium Lactate in Severe TBI · Phase 2 · not yet recruiting
NCT04996667 — Effect of iNO in Patients With Submassive and Massive PE · Phase 2 · withdrawn
NCT05067387 — Evaluation of Oral THC and CBD in Men and Women · Phase 1 · not yet recruiting
NCT07534696 — Evaluation of Non-Invasive Pelvic Floor Neuromuscular Stimulation for Urinary Incontinence After Prostatectomy · NA · not yet recruiting

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT03451435 (US National Library of Medicine, public domain)
Publications: Europe PMC API search by NCT ID, retrieved 10 June 2026
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by University of California, Los Angeles
Last refreshed: 21 January 2026

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT03451435.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing